{
  "docId": "019de070-c3f1-763f-aec8-8e853cc1bc89",
  "docSlug": "f47b98abe226393f6e944eb87df3d4ec",
  "documentTitle": "AbCellera | Results Presentation Deck | 23 slides",
  "authorId": "abcellera",
  "authorName": "AbCellera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.5458937,
  "pageNumber": 9,
  "pageCount": 23,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "timeline",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a visual timeline to highlight the speed of the R&D process.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-c3f1-763f-aec8-8e853cc1bc89/9",
  "deckHref": "/decks/019de070-c3f1-763f-aec8-8e853cc1bc89",
  "deckJsonHref": "/decks/019de070-c3f1-763f-aec8-8e853cc1bc89.json",
  "deckAnchorHref": "/decks/019de070-c3f1-763f-aec8-8e853cc1bc89#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.9,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "diagram",
      "text": "From patient sample to human testing in 90 days",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ff0e2f5-8f21-4942-a864-a74a4898bfcc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.12,
        "x": 0.35,
        "y": 0.65
      },
      "kind": "metric",
      "text": "~5,800,000 cells screened in 3 days",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7586a310-32f1-4dc1-8730-c41e391feb62",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.12,
        "x": 0.52,
        "y": 0.65
      },
      "kind": "metric",
      "text": "24 leads identified in 23 days",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7a0bc61-9d6c-4f55-85bc-a4a5998e38c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.62,
        "x": 0.19,
        "y": 0.24
      },
      "kind": "paragraph",
      "text": "Together with its partners, AbCellera brought the first treatment developed specifically for COVID-19. Bamlanivimab is currently authorized in 15 countries, including the United States, Canada, Europe and the Middle East for the treatment of mild to moderate COVID-19 in high-risk patients.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85dedee9-dfac-4a33-aa98-dd536611a34a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.66,
        "x": 0.17,
        "y": 0.14
      },
      "kind": "title",
      "text": "THE 1ST COVID-19 ANTIBODY TREATMENT TO REACH THE CLINIC IN N. AMERICA.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1bd384e4-1ddb-406b-b182-7f42d4bc07ad",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "99661251-dc88-4417-94c1-4645cee815ba",
      "evidence": "Visual progression from Day 0 to Day 90",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 9,
      "from": 8,
      "beatId": "b63f5576-800e-4e9b-b6bb-8f691df40005",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Timeline",
      "beatSlug": null,
      "evidence": "The document presents a timeline of AbCellera's achievements, including the first COVID-19 antibody treatment to reach the clinic in North America.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "282f258a-6e2e-44b5-a8f4-77f2fc333813",
      "evidence": "The document presents the number of patients treated with bamlanivimab, highlighting the impact of AbCellera's technology.",
      "position": 0,
      "objective": "What are the consequences of not addressing COVID-19?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}